Johnson & Johnson – Product Pipeline Review – Q2 2011
Global Market Direct’s pharmaceuticals report, “Johnson & Johnson - Product Pipeline Review - Q2 2011” provides data on the Johnson & Johnson’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Johnson & Johnson’s corporate website, SEC filings, investor presentations and featured press releases, both from Johnson & Johnson and industry-specific third party sources, put together by Global Markets Direct’s team.
- Johnson & Johnson - Brief Johnson & Johnson overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Johnson & Johnson human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Johnson & Johnson with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Johnson & Johnson’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Johnson & Johnson’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Johnson & Johnson in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Johnson & Johnson’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportuniti
Johnson & Johnson – Product Pipeline Review – Q2 2011 Reference Code: GMDHC1347CDB Publication Date: AUG 2011 Johnson & Johnson – Product Pipeline Review – Q2 2011 GMDHC1347CDB / Published AUG 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Johnson & Johnson – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 16 List of Figures 17 Johnson & Johnson Snapshot 18 Johnson & Johnson Overview 18 Key Information 18 Key Facts 18 Johnson & Johnson – Research and Development Overview 19 Key Therapeutic Areas 19 Johnson & Johnson – Pipeline Review 27 Pipeline Products by Stage of Development 27 Pipeline Products – Monotherapy 28 Pipeline Products – Combination Treatment Modalities 29 Johnson & Johnson – Pipeline Products Glance 30 Johnson & Johnson – Late Stage Pipeline 30 Registration Filed Products/Combination Treatment Modalities 30 Phase III Products/Combination Treatment Modalities 31 Johnson & Johnson Clinical Stage Pipeline Products 32 Phase II Products/Combination Treatment Modalities 32 Phase I Products/Combination Treatment Modalities 35 Johnson & Johnson–Early Stage Pipeline Products 37 Pre-Clinical Products/Combination Treatment Modalities 37 Discovery Products/Combination Treatment Modalities 38 Johnson & Johnson – Drug Profiles 39 AAB-002 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Abiraterone Acetate + Leuprolide Acetate + Prednisone 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Abiraterone Acetate + Prednisone + Leuprolide 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ACC-001 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ADX71149 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Beta Secretase Inhibitor 44 Product Description 44 Johnson & Johnson – Product Pipeline Review – Q2 2011 GMDHC1347CDB / Published AUG 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Johnson & Johnson – Product Pipeline Review Mechanism of Action 44 R&D Progress 44 Carisbamate 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CB3304 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CB6604 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CL184 + Rabies Vaccine 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CNTO 1959 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CNTO 2476 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CNTO 3157 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CNTO 328 + Mitoxantrone + Prednisone 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 CNTO 888 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CNTO 888 + Liposomal Doxorubicin Hydrochloride 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 CNTO 888 + Docetaxel 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CNTO 888 + Gemcitabine 57 Product Description 57 Johnson & Johnson – Product Pipeline Review – Q2 2011 GMDHC1347CDB / Published AUG 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(3) Johnson & Johnson – Product Pipeline Review Mechanism of Action 57 R&D Progress 57 CNTO 888 + Paclitaxel + Carboplatin 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CNTO 95 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CNTO 95 + Docetaxel + Prednisone 60 Product Description 60 Mechanism of Action 60 R&D Progress 61 Crucell Ad35 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Dacogen 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Dacogen
Pages to are hidden for
"Johnson & Johnson – Product Pipeline Review – Q2 2011"Please download to view full document